Advertisement

Clinical Presentations of Myasthenia Gravis

  • Jan B. M. Kuks
Chapter
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

This chapter describes signs and symptoms characteristic for postsynaptic neuromuscular junction diseases, how to validate them, and when to attribute them to myasthenia or another neurological disease. Non-motor symptoms in myasthenia will be discussed separately with a special reference to “fatigue.” We propose a bedside examination policy. The clinical course of myasthenia and how it may be influenced by external factors are described; several clinical subgroups are identified: congenital vs. acquired, anti-AChR vs. anti-MuSK vs. seronegative, pure ocular vs. generalized, thymoma vs. no thymoma, and early onset vs. late onset in a-AChR+ patient.

The epidemiology of myasthenia is described for the whole population of patients and according to age, gender, and thymic histology. Familial autoimmune myasthenia and congenital myasthenia are described separately. The increase in incidence and prevalence and the shift to “old age” are discussed and explained by increase of life expectancy, improvement of general knowledge on myasthenia, and new diagnostic tests.

Keywords

Myasthenia AChR antibodies MuSK antibodies Thymoma Juvenile MG Neonatal MG Congenital MG Early onset Late onset Epidemiology Ocular symptoms Bulbar symptoms Generalized symptoms Ventilatory insufficiency Non-motor symptoms Autonomic symptoms Sensory symptoms Fatigue 

References

  1. 1.
    Almog Y, Ben-David M, Nemet AY. Inferior oblique muscle paresis as a sign of myasthenia gravis. J Clin Neurosci. 2016;25:50–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Sylva M, Van der Kooi AJ, Grolman W. Dyspnoea due to vocal fold abduction paresis in anti-MuSK myasthenia gravis. J Neurol Neurosurg Psychiatry. 2008;79:1083–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Osei-Lah A, Reilly V, Capildeo BJ. Bilateral abductor vocal fold paralysis due to myasthenia gravis. J Laryngol Otol. 1999;113:678–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Huybers MG, Niks EH, Klooster R, de Visser M, Kuks JB, Velding JH, et al. Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscul Disord. 2016;26:350–3.CrossRefGoogle Scholar
  5. 5.
    Weijnen FG, van der Bilt A, Wokke J, Kuks J, van der Glas HW, Bosman F. What’s in a smile? Quantification of the vertical smile of patients with myasthenia gravis. J Neurol Sci. 2000;173:124–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Weijnen FG, Van der Bilt A, Wokke JHJ, Kuks JBM, Van der Glas HW, Bosman F. Maximal bite force and surface EMG in patients with myasthenia gravis. Muscle Nerve. 2000;23:1694–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Weijnen FG, Kuks JBM, Van der Bilt, Van der Glas HW, Wassenberg MWM, Bosman F. Tongue force in patients with myasthenia gravis. Acta Neurol Scand. 2000;102:303–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Konstantopoulos K, Christou Y-P, Vogazianos P, Zamba-Papicolaou E, Kleopa KA. A quantitative method for the assessment of dysarthrophonia in myasthenia gravis. J Neurol Sci. 2017;377:42–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Domingo CA, Landau ME, Campbell WW. Selective triceps muscle weakness in myasthenia gravis is under-recognized. J Clin Neuromuscul Dis. 2016;18:103–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Vecchio D, Varrasi C, Comi C, Ripellino P, Cantello R. A patients with autoimmune limb-girdle myasthenia, and a brief review of this treatable condition. Clin Neurol Neurosurg. 2017;58:53–5.CrossRefGoogle Scholar
  11. 11.
    Cejvanovic S, Vissing J. Muscle strength in myasthenia gravis. Acta Neurol Scand. 2014;129:367–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Fitzgerald MG, Shafritz AB. Distal myasthenia gravis. J Hand Surg Am. 2014;39:1419–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Mongiovi PC, Elsheikh E, Lawson VH, Kissel JT, Arnold WD. Neuromuscular junction disorders mimicking myopathy. Muscle Nerve. 2014;50:854–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Oosterhuis HJGH. Myasthenia gravis. Edinburgh: Churchill Livingstone; 1984.Google Scholar
  15. 15.
    Reuther P, Hertel G, Ricker K, Bürkner R. Lungenfunktionsdiagnostik bei myasthenia gravis. Verhandlungen der Deutsche Gesellschaft für Innere Medizin. 1978;84:1579–82.Google Scholar
  16. 16.
    Kuks JBM, Oosterhuis HJGH. Disorders of the neuromuscular junction: outcome measures and clinical scales. In: Guiloff RJ, editor. Clinical trials in neurology. London: Springer; 2001. p. 485–99.CrossRefGoogle Scholar
  17. 17.
    Oosterhuis HJGH, Bethlem J. Neurogenic muscle involvement in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1973;36:244–54.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Osserman KE. Myasthenia gravis. New York: Grune & Stratton; 1958.Google Scholar
  19. 19.
    Oosterhuis HJGH. Myasthenia gravis. Groningen: Neurological Press; 1997.Google Scholar
  20. 20.
    Farrugia ME, Robson MD, Clover L. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain. 2006;129:1481–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Suzuki S, Utsugisawa K, Suzuki N. Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2013;84:989–94.CrossRefPubMedGoogle Scholar
  22. 22.
    Whiting PJ, Cooper J, Lindstrom JM. Antibodies in sera from patients with myasthenia gravis do not bind with nicotinic acetylcholine receptors from human brain. J Neuroimmunol. 1987;16:205.CrossRefPubMedGoogle Scholar
  23. 23.
    Mao Z, Yin J, Lu Z, Hu X. Association between myasthenia gravis and cognitive function: a systematic review and meta-analysis. Ann Indian Acad Neurol. 2015;18:131–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci. 2001;88:187–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Shukla G, Gupta S, Goyal V, Singh S, Srivastava A, Behari M. Abnormal sympathetic hyper-reactivity in patients with myasthenia gravis: a prospective study. Clin Neurol Neurosurg. 2013;115:179–86.CrossRefPubMedGoogle Scholar
  26. 26.
    Peric S, Rakocevic-Stojanovic V, Nisic T, Pavlovic S, Basta I, Popovic S, et al. Cardiac autonomic control in patients with myasthenia gravis and thymoma. J Neurol Sci. 2011;307(1–2):30–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Puneeth CS, Chandra SR, Yadav R, Sathyaprabha TN, Chandran S. Heartrate and blood pressure variability in patients with myasthenia gravis. Ann Indian Acad Neurol. 2013;16:329–32.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Leon-Samiento FE, Leon-Ariza JS, Prad D, Leon-Aziza DS, Rizzo-Sierra CV. Sensory aspects in myasthenia gravis: a translational approach. J Neurol Sci. 2016;368:379–88.CrossRefGoogle Scholar
  29. 29.
    Symonette CJ, Watson BV, Koopman WJ, Micolle MW. Doherty. Muslce strength and fatigue in patients with generalized myasthenia gravis. Muscle Nerve. 2010;41:362–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Jordan B, Mehl T, Schweden TLK, Menge U, Zierz S. Assessment of physical fatigability and fatigue perception in myasthenia gravis. Nuscle Nerve. 2017;55:657–63.CrossRefGoogle Scholar
  31. 31.
    Elsais A, Wyller VB, Loge JH, Kerty E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol. 2013;13:132–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Suarez GA, Kelly JJ. The dropped head syndrome. Neurology. 1992;42:1625–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48:143–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-Musk- vs. anti-AChr_positive and seronegative myasthenia gravis. Neurology. 2007;68:609–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Niks EH, Kuks JBM, Roep BO, Haasnoot GW, Verduijn W, Ballieux EPB, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006;66:1772–4.CrossRefPubMedGoogle Scholar
  37. 37.
    Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA-antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103:579–601.CrossRefPubMedGoogle Scholar
  38. 38.
    Oosterhuis HJGH. Myasthenia gravis. A review. Clin Neurol Neurosurg. 1981;83:105–35.CrossRefPubMedGoogle Scholar
  39. 39.
    Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and the effect of various therapeutic measures. Ann N Y Acad Sci. 1981;377:652–69.CrossRefPubMedGoogle Scholar
  40. 40.
    Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol Sci. 1997;244:112–8.CrossRefGoogle Scholar
  41. 41.
    Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci. 1981;377:670–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Oosterhuis HJGH. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann N Y Acad Sci. 1981;377:678–89.CrossRefPubMedGoogle Scholar
  43. 43.
    Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med. 1997;157:399–408.CrossRefPubMedGoogle Scholar
  44. 44.
    Myasthenia Gravis Foundation of America. Drugs to avoid. www.myasthenia.org/livingwithMG/DrugstoAvoid.aspx.
  45. 45.
    Auriel E, Regev K, Dori A, Karni A. Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve. 2011;43:893–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Schalke B. Klinische Besonderheiten bei myasthenia gravis patienten. Akt Neurologie. 1998;25:528–9.Google Scholar
  47. 47.
    Plauché WC. Myasthenia gravis in pregnancy: an update. Am J Obstet Gynecol. 1979;135:691–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Batocchi AP, Majolini L, Evoli A, Lino MM, Minisci C, Tonali P. Course and treatment of myasthenia gravis during pregnancy. Neurology. 1999;52:447–52.CrossRefPubMedGoogle Scholar
  49. 49.
    Leker RR, Karni A, Abramski O. Exacerbation of myasthenia during the menstrual period. J Neurol Sci. 1998;156:107–11.CrossRefPubMedGoogle Scholar
  50. 50.
    Borenstein S, Desmedt JE. Temperature and weather correlates of myasthenia fatigue. Lancet. 1974;ii:63–6.CrossRefGoogle Scholar
  51. 51.
    Guttman L. Heat-induced myasthenic crises. Arch Neurol. 1980;37:671–2.CrossRefGoogle Scholar
  52. 52.
    Oosterhuis HJGH. The natural course of myasthenia gravis: a longterm follow-up study. J Neurol Neurosurg Psychiatry. 1989;52:1121–7.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive population survey. Arch Neurol. 1991;48:733–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Storm Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand. 1984;70:274–84.CrossRefPubMedGoogle Scholar
  55. 55.
    Aragonès JM, Bolíbar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I. Myasthenia gravis. A higher than expected incidence in the elderly. Neurology. 2003;60:1024–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Emilio Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study. Neurology. 1998;51:255–8.CrossRefGoogle Scholar
  57. 57.
    D’Alessandro R, Granieri E, Benassi G, Tola MR, Casmiro M, Mazzanti B, et al. Comparative study on the prevalence of myasthenia gravis in the provinces of Bologna and Ferrara, Italy. Acta Neurol Scand. 1991;2:83–8.CrossRefGoogle Scholar
  58. 58.
    Phillips LH, Tomer JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42:1888–93.CrossRefPubMedGoogle Scholar
  59. 59.
    Pirskanen R. Genetic aspects in myasthenia gravis, a family study of 264 Finnish patients. Acta Neurol Scand. 1977;56:365–88.CrossRefPubMedGoogle Scholar
  60. 60.
    Sorensen TT, Holm EB. Myasthenia gravis in the county of Viborg, Denmark. Eur Neurol. 1989;29:177–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Robertson NP, Deans J, Compston DAS. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry. 1998;65:492–6.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Carr AS, Cardwell CR, McCarron PO, McConvill J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46–54.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    McGrogan A, Sneddon S, De Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34:171–83.CrossRefPubMedGoogle Scholar
  64. 64.
    Pallaver F, Riviera AP, Piffer S, Ricciard R, Roni R, Orrico D, et al. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011;36:282–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, et al. Myasthenia gravis: epidemiological data and prognostic factors. Ann N Y Acad Sci. 2003;998:413–23.CrossRefPubMedGoogle Scholar
  66. 66.
    Casetta I, Groppo E, De Gennaro R, Cesnik E, Piccolo I, Volpato S, et al. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010;257:2015–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016;26:41–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Niks EH, Kuks JBM, Verschuuren JJGM. Epidemiology of myasthenia gravis with anti-MuSK antibodies in the Netherlands. J Neurol Neursurg Psychiatry. 2007;78:417–8.CrossRefGoogle Scholar
  69. 69.
    Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472.CrossRefPubMedGoogle Scholar
  70. 70.
    Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol Sci. 1990;237:339–44.CrossRefGoogle Scholar
  71. 71.
    Potagas C, Dellatotas G, Tavernarakis A, Molari H, Mourtzouhou P, Koutra H, et al. Myasthenia gravis: changes observed in a 30-years retrospective clinical study of a hospital-based population. J Neurol. 2004;251(1):116–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Matsuda M, Dohi-Iijima N, Nakamura A, Sekijima Y, Moriat H, Matsuzawa S, et al. Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano prefecture, Japan. Intern Med. 2005;44:572–7.CrossRefPubMedGoogle Scholar
  73. 73.
    Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology. 2005;65:928–30.CrossRefPubMedGoogle Scholar
  74. 74.
    Fukuyama Y, Hirayama Y, Osawa M. Epidemiological and clinical features of childhood myasthenia gravis in Japan. Tokyo: Japan Medical Research Foundation, University of Tokyo Press; 1981. p. 19.Google Scholar
  75. 75.
    Hawkins BR, Yu YL, Wong V, Woo E, IpM S, Dawkins RL. Possible evidence of a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients. Q J Med. 1989;70:235–41.PubMedGoogle Scholar
  76. 76.
    Wong V, Hawkins BR, Yu YL. Myasthenia gravis in Hong Kong Chinese. Acta Neurol Scand. 1992;86:68–72.CrossRefPubMedGoogle Scholar
  77. 77.
    Batocchi AP, Evoli A, Palmisani MT, Lo Monaco M, Bartoccioni M, Tonali P. Early onset myasthenia gravis: clinical characteristics and response to therapy. Eur J Pediatr. 1990;150:66–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Lindner A, Schalke B, Toyka KV. Outcome of juvenile-onset myasthenia gravis: a retrospective study with long term follow-up of 79 patients. J Neurol. 1997;244:515–20.CrossRefPubMedGoogle Scholar
  79. 79.
    Chiang LM, Darras BT, Kang POB. Juvenile myasthenia gravis. Muscle Nerve. 2009;39:423–31.CrossRefPubMedGoogle Scholar
  80. 80.
    Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci. 2013;325:1–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Antonini G, Morino S, Gragnani F, Fiorelli M. Myasthenia gravis in the elderly: a hospital based study. Acta Neurol Scand. 1996;93:260–2.CrossRefPubMedGoogle Scholar
  82. 82.
    Aarli JA. Late-onset myasthenia gravis. Arch Neurol. 1999;56:25–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Kuks JBM, Limburg PC, Horst G, Oosterhuis HJGH. Antibodies to skeletal muscle in myasthenia gravis, part 2. Prevalence in non-thymoma patients. J Neurol Sci. 1993;120:78–81.CrossRefPubMedGoogle Scholar
  84. 84.
    Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology. 1990;40:786–90.CrossRefPubMedGoogle Scholar
  85. 85.
    Bril V, Kojic J, Dhanani A. The long-term clinical outcome of myasthenia gravis in patients with thymoma. Neurology. 1998;51:1198–200.CrossRefPubMedGoogle Scholar
  86. 86.
    Simpson JA. Myasthenia gravis, a new hypothesis. Scott Med J. 1960;5:419–36.CrossRefGoogle Scholar
  87. 87.
    Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ. Associated disorders in myasthenia gravis: autoimmune disease and their relation to thymectomy. Acta Neurol Scand. 1989;80:290–5.CrossRefPubMedGoogle Scholar
  88. 88.
    Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune disease in the United States. Clin Immunol Immunopathol. 1997;84:223–43.CrossRefPubMedGoogle Scholar
  89. 89.
    Namba T, Brunner NG, Brown SB, Muguruma M, Grob D. Familial myasthenia gravis. Arch Neurol. 1971;25:49–60.CrossRefPubMedGoogle Scholar
  90. 90.
    Szobor A. Myasthenia gravis: familial occurrence, a study of 1100 myasthenia gravis patients. Acta Med Hung. 1989;4:13.Google Scholar
  91. 91.
    Marrie RA, Sahlas DJ, Brftay GM. Familial autoimmune myasthenia gravis: four patients involving three generations. Can J Neurol Sci. 2000;27:307–10.CrossRefPubMedGoogle Scholar
  92. 92.
    Chen Y, Wang W, Wei D, Yan L. Three cases of myasthenia gravis from one family with variations in clinical features and serum antibodies. Neuromuscul Disord. 2012;22:286–8.CrossRefPubMedGoogle Scholar
  93. 93.
    Behan PO. Immune disease and HLA association with myasthenia gravis. J Neurol Neurosurg Psychiatry. 1980;4:611–21.CrossRefGoogle Scholar
  94. 94.
    Evoli A, Batocchi AP, Zelano G, Uncini A, Palmisani MT, Tonali P. Familial autoimmune myasthenia gravis: report of four families. J Neurol Neurosurg Psychiatry. 1995;58:729–31.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Bergoffen J, Zmyewski CM, Fischbeck KH. Familial autoimmune myasthenia gravis. Neurology. 1994;44:551–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyUniversity Medical Centre GroningenGroningenThe Netherlands

Personalised recommendations